162 related articles for article (PubMed ID: 33568214)
1. High activity and low toxicity of a novel CD71-targeting nanotherapeutic named The-0504 on preclinical models of several human aggressive tumors.
Falvo E; Damiani V; Conti G; Boschi F; Messana K; Giacomini P; Milella M; De Laurenzi V; Morea V; Sala G; Fracasso G; Ceci P
J Exp Clin Cancer Res; 2021 Feb; 40(1):63. PubMed ID: 33568214
[TBL] [Abstract][Full Text] [Related]
2. Widespread in vivo efficacy of The-0504: A conditionally-activatable nanoferritin for tumor-agnostic targeting of CD71-expressing cancers.
Fracasso G; Falvo E; Tisci G; Sala G; Colotti G; Cingarlini S; Tito C; Bibbo S; Frusteri C; Tremante E; Giordani E; Giacomini P; Ceci P
Heliyon; 2023 Oct; 9(10):e20770. PubMed ID: 37860543
[TBL] [Abstract][Full Text] [Related]
3. Targeted delivery of siRNA using transferrin-coupled lipoplexes specifically sensitizes CD71 high expressing malignant cells to antibody-mediated complement attack.
Cinci M; Mamidi S; Li W; Fehring V; Kirschfink M
Target Oncol; 2015 Sep; 10(3):405-13. PubMed ID: 25395366
[TBL] [Abstract][Full Text] [Related]
4. Engineered Human Nanoferritin Bearing the Drug Genz-644282 for Cancer Therapy.
Falvo E; Arcovito A; Conti G; Cipolla G; Pitea M; Morea V; Damiani V; Sala G; Fracasso G; Ceci P
Pharmaceutics; 2020 Oct; 12(10):. PubMed ID: 33092088
[TBL] [Abstract][Full Text] [Related]
5. CD71
Leung TH; Tang HW; Siu MK; Chan DW; Chan KK; Cheung AN; Ngan HY
Mol Cancer Res; 2019 Sep; 17(9):1867-1880. PubMed ID: 31235657
[TBL] [Abstract][Full Text] [Related]
6. Aberrant expression of TfR1/CD71 in thyroid carcinomas identifies a novel potential diagnostic marker and therapeutic target.
Magro G; Cataldo I; Amico P; Torrisi A; Vecchio GM; Parenti R; Asioli S; Recupero D; D'Agata V; Mucignat MT; Perris R
Thyroid; 2011 Mar; 21(3):267-77. PubMed ID: 21323588
[TBL] [Abstract][Full Text] [Related]
7. Selection and identification of transferrin receptor-specific peptides as recognition probes for cancer cells.
Tan Y; Liu W; Zhu Z; Lang L; Wang J; Huang M; Zhang M; Yang C
Anal Bioanal Chem; 2018 Jan; 410(3):1071-1077. PubMed ID: 29046922
[TBL] [Abstract][Full Text] [Related]
8. Bioengineered Ferritin Nanocarriers for Cancer Therapy.
Sun X; Hong Y; Gong Y; Zheng S; Xie D
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34209892
[TBL] [Abstract][Full Text] [Related]
9. Absence of CD71 transferrin receptor characterizes human gastric adenosquamous carcinoma stem cells.
Ohkuma M; Haraguchi N; Ishii H; Mimori K; Tanaka F; Kim HM; Shimomura M; Hirose H; Yanaga K; Mori M
Ann Surg Oncol; 2012 Apr; 19(4):1357-64. PubMed ID: 21523522
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of transferrin receptor CD71 and its tumorigenic properties in esophageal squamous cell carcinoma.
Chan KT; Choi MY; Lai KK; Tan W; Tung LN; Lam HY; Tong DK; Lee NP; Law S
Oncol Rep; 2014 Mar; 31(3):1296-304. PubMed ID: 24435655
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Value of Transferrin Receptor-1 (CD71) Expression in Acute Lymphoblastic Leukemia.
Hagag AA; Badraia IM; Abdelmageed MM; Hablas NM; Hazzaa SME; Nosair NA
Endocr Metab Immune Disord Drug Targets; 2018; 18(6):610-617. PubMed ID: 29875008
[TBL] [Abstract][Full Text] [Related]
12. The effect of protein expression on cancer cell capture using the Human Transferrin Receptor (CD71) as an affinity ligand.
Lyons VJ; Helms A; Pappas D
Anal Chim Acta; 2019 Oct; 1076():154-161. PubMed ID: 31203960
[TBL] [Abstract][Full Text] [Related]
13. Targeting urokinase and the transferrin receptor with novel, anti-mitotic N-alkylisatin cytotoxin conjugates causes selective cancer cell death and reduces tumor growth.
Vine KL; Indira Chandran V; Locke JM; Matesic L; Lee J; Skropeta D; Bremner JB; Ranson M
Curr Cancer Drug Targets; 2012 Jan; 12(1):64-73. PubMed ID: 22111834
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive Cell Surface Antigen Analysis Identifies Transferrin Receptor Protein-1 (CD71) as a Negative Selection Marker for Human Neuronal Cells.
Menon V; Thomas R; Elgueta C; Horl M; Osborn T; Hallett PJ; Bartos M; Isacson O; Pruszak J
Stem Cells; 2019 Oct; 37(10):1293-1306. PubMed ID: 31381839
[TBL] [Abstract][Full Text] [Related]
15. Elucidation and Structural Modeling of CD71 as a Molecular Target for Cell-Specific Aptamer Binding.
Wu X; Liu H; Han D; Peng B; Zhang H; Zhang L; Li J; Liu J; Cui C; Fang S; Li M; Ye M; Tan W
J Am Chem Soc; 2019 Jul; 141(27):10760-10769. PubMed ID: 31185171
[TBL] [Abstract][Full Text] [Related]
16. Novel lncRNA-IUR suppresses Bcr-Abl-induced tumorigenesis through regulation of STAT5-CD71 pathway.
Wang X; Yang J; Guo G; Feng R; Chen K; Liao Y; Zhang L; Sun L; Huang S; Chen JL
Mol Cancer; 2019 Apr; 18(1):84. PubMed ID: 30961617
[TBL] [Abstract][Full Text] [Related]
17. Targeting the Difficult-to-Drug CD71 and MYCN with Gambogic Acid and Vorinostat in a Class of Neuroblastomas.
Bishayee K; Habib K; Sadra A; Huh SO
Cell Physiol Biochem; 2019; 53(1):258-280. PubMed ID: 31313541
[TBL] [Abstract][Full Text] [Related]
18. Cytometric evaluation of transferrin receptor 1 (CD71) in childhood acute lymphoblastic leukemia.
Płoszyńska A; Ruckemann-Dziurdzińska K; Jóźwik A; Mikosik A; Lisowska K; Balcerska A; Witkowski JM
Folia Histochem Cytobiol; 2012 Jul; 50(2):304-11. PubMed ID: 22763969
[TBL] [Abstract][Full Text] [Related]
19. H-Ferritin-nanocaged olaparib: a promising choice for both BRCA-mutated and sporadic triple negative breast cancer.
Mazzucchelli S; Truffi M; Baccarini F; Beretta M; Sorrentino L; Bellini M; Rizzuto MA; Ottria R; Ravelli A; Ciuffreda P; Prosperi D; Corsi F
Sci Rep; 2017 Aug; 7(1):7505. PubMed ID: 28790402
[TBL] [Abstract][Full Text] [Related]
20. CD71 is selectively and ubiquitously expressed at high levels in erythroid precursors of all maturation stages: a comparative immunochemical study with glycophorin A and hemoglobin A.
Dong HY; Wilkes S; Yang H
Am J Surg Pathol; 2011 May; 35(5):723-32. PubMed ID: 21415701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
